65547-98-0

Upstream product

• 10298-80-3 2-chloro-5-methoxynitrobenzene 
• 105-56-6 ethyl 2-cyanoacetate 

Downstream Products

• 20876-30-6 (4-methoxy-2-nitro-phenyl)-acetic acid 
• 691900-61-5 C₁₅H₁₂N₂O₂ 
• 691900-59-1 6-methoxy-1H-indazole-3-carbonitrile 
• 118671-03-7 2-(2-amino-4-methoxyphenyl)acetonitrile 
• 1334784-90-5 (2-acetylamino-4-methoxy-phenyl)-acetic acid 
• 1334784-89-2 (2-acetylamino-4-methoxy-phenyl)-acetic acid methyl ester 
• 90923-03-8 (4-methoxy-2-nitro-phenyl)-acetic acid methyl ester 
• 105003-90-5 (4-methoxy-2-nitro-phenyl)-acetonitrile 
• 160292-75-1 3-Amino-4-(4-methoxy-2-nitro-phenyl)-2H-isoxazol-5-one 
• 160292-70-6 (N-Hydroxycarbamimidoyl)-(4-methoxy-2-nitro-phenyl)-acetic acid ethyl ester 
• 154373-05-4 5-Amino-4-(4-methoxy-2-nitro-phenyl)-1H-pyrazol-3-ol 

Relevant academic research and scientific papers

ETHER COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I" and I? or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5] NONANE DERIVATIVES

The present invention provides a compound of Formula (I) or a pharmaceutically salt thereof wherein R1, R2, Ra, L, Z, Z1 and Z2 are as defined herein, that act as Ghrelin antagonists or inverse agonists; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by the antagonism of the Ghrelin receptor.

Wavelength-selective photoactivatable protecting groups for thiols

We developed and characterized efficient, remarkably water-soluble photolabile protecting groups for thiols based on 2-nitrobenzyl and (coumarin-4-yl)methyl chromophores, among them two new ones. The protecting groups allow, due to their different absorpt

OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION

This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relate

OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION

This invention relates to potent potassium channel blocker compounds of Formula (I) or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also rela

Ophthalmic compositions for treating ocular hypertension

This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relate